Seaport Therapeutics, Inc. (SPTX) — SEC Filings
Seaport Therapeutics, Inc. (SPTX) — 14 SEC filings. Latest: 3 (May 1, 2026). Includes 12 3, 1 S-1MEF, 1 S-1/A. AI-decoded analysis.
View Seaport Therapeutics, Inc. on SEC EDGAR
Overview
Seaport Therapeutics, Inc. (SPTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on May 1, 2026: On April 30, 2026, Seaport Therapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates the initial reporting of ownership for certain individuals or entities related to the company. The filing was accepted by the SEC on the same date.
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 14 neutral. The dominant filing sentiment for Seaport Therapeutics, Inc. is neutral.
Filing Type Overview
Seaport Therapeutics, Inc. (SPTX) has filed 12 3, 1 S-1MEF, 1 S-1/A with the SEC between Apr 2026 to May 2026.
Recent SEC Filings (14)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | 3 Filing | |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | 3 Filing | |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | Seaport Therapeutics Files Initial Ownership Statement | low |
| May 1, 2026 | 3 | 3 Filing | |
| Apr 30, 2026 | S-1MEF | Seaport Therapeutics Files S-1MEF for Security Registration | medium |
| Apr 27, 2026 | S-1/A | Seaport Therapeutics Files S-1/A Amendment | medium |
Risk Profile
Risk Assessment: Of SPTX's 11 recent filings, 0 were flagged as high-risk, 2 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- PETERSON SANDRA E
- 0001192752
- Zohar Daphne
- Mates Sharon
- Denice Torres
- 0001820278
- Jason Pitts
- 0001821346
- David E. Wheadon
- 0001789507
- Healy James
- 0001245624
- Keith Crandell
- Robert Nelsen
- Steven Gillis
Top Tags
insider-filing (9) · ownership (9) · initial-statement (3) · pharmaceuticals (2) · initial-filing (1) · sec-form-3 (1) · disclosure (1) · securities (1) · registration-statement (1) · securities-offering (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 2026-04-30 | Date of the initial ownership statement filing. |
| CIK Number | 0002042347 | Identifier for Seaport Therapeutics, Inc. |
| CIK | 0002042347 | Seaport Therapeutics, Inc. identifier |
| File Number | 001-43254 | Related to Form 3 filing |
| Form Type | S-1MEF | Indicates registration of additional securities under a prior S-1 |
| Accession Number | 0001193125-26-198107 | Unique identifier for the SEC filing |
Frequently Asked Questions
What are the latest SEC filings for Seaport Therapeutics, Inc. (SPTX)?
Seaport Therapeutics, Inc. has 14 recent SEC filings from Apr 2026 to May 2026, including 12 3, 1 S-1MEF, 1 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SPTX filings?
Across 14 filings, the sentiment breakdown is: 14 neutral. The dominant sentiment is neutral.
Where can I find Seaport Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Seaport Therapeutics, Inc. (SPTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Seaport Therapeutics, Inc.?
Financial highlights for Seaport Therapeutics, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for SPTX?
Investment thesis data for SPTX will be available once enriched filings are processed.
Who are the key executives at Seaport Therapeutics, Inc.?
Key executives identified across Seaport Therapeutics, Inc.'s filings include PETERSON SANDRA E, 0001192752, Zohar Daphne, Mates Sharon, Denice Torres and 13 others.
What are the main risk factors for Seaport Therapeutics, Inc. stock?
Of SPTX's 11 assessed filings, 0 were flagged high-risk, 2 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Seaport Therapeutics, Inc.?
Forward guidance and predictions for Seaport Therapeutics, Inc. are extracted from SEC filings as they are enriched.